Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viral Mutations00:36

Viral Mutations

40.6K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
40.6K
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.3K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.3K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

13.9K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-omics profiling and bile-acid exposure assays implicate a gut microbiome-parasite axis linked to persistent Entamoeba histolytica carriage.

Gut pathogens·2026
Same author

Prevalence and clinical characteristics of HIV/sexually transmitted infections among transgender and gender-diverse individuals attending a gender-affirming clinic in Japan: A descriptive clinical-based study.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2026
Same author

Recurrent herpes simplex virus type 2 Mollaret meningitis in a man living with HIV: A case report and patient-initiated episodic valacyclovir strategy.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Multistep coevolution of HIV-1 and human leukocyte antigen-C-restricted HIV-1-specific CD8<sup>+</sup> T cells and the association with disease progression.

PNAS nexus·2026
Same author

Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

The lancet. HIV·2026
Same author

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial.

Lancet (London, England)·2026

Related Experiment Video

Updated: Mar 19, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K

Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations.

Tsunefusa Hayashida1, Atsuko Hachiya2, Hirotaka Ode2

  • 1AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.

The Journal of Antimicrobial Chemotherapy
|June 23, 2016
PubMed
Summary

The E138K mutation confers low resistance to rilpivirine. However, its combination with I135T/L mutations significantly amplifies resistance, impacting antiviral therapy effectiveness for HIV-1.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K
Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

2.0K

Related Experiment Videos

Last Updated: Mar 19, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K
Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

2.0K

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • Rilpivirine is a key drug in current Antiretroviral Therapy (ART) guidelines.
  • The E138K mutation in HIV-1 reverse transcriptase (RT) confers low-level resistance to rilpivirine.
  • An unknown mechanism may amplify the resistance conferred by E138K.

Purpose of the Study:

  • To elucidate the mechanism responsible for amplifying rilpivirine resistance associated with the E138K mutation.
  • To investigate the role of co-occurring mutations in enhancing HIV-1 resistance to rilpivirine.

Main Methods:

  • Comparison of HIV-1 RT sequences from patients experiencing virological failure on rilpivirine-containing ART.
  • Analysis of recombinant HIV-1 variants to assess the susceptibility to rilpivirine in the presence of specific mutations.

Main Results:

  • Virological treatment failure occurred in six out of 162 patients on rilpivirine-containing ART.
  • E138K mutation emerged in three patients; other resistance mutations emerged in the remaining three.
  • Coexistence of I135T/L mutations with E138K significantly amplified rilpivirine resistance.

Conclusions:

  • The E138K mutation alone confers minimal resistance to rilpivirine.
  • The presence of I135T/L mutations alongside E138K amplifies rilpivirine resistance.
  • Prevalent HLA-B*51/52 escape mutations (I135T/L) in Japan may predispose HIV-1 to E138K under rilpivirine pressure, influencing drug resistance patterns.